Seoul National University Hospital
Seoul, South Korea
NCT Number: NCT07742813
The purpose of this retrospective study is to evaluate the clinical performance of Vital-PICASO, an artificial intelligence-based biological signal analysis software designed to predict the risk of hypoxia within 24 hours using vital-sign data from adult general ward inpatients.
Electronic medical record data from patients aged 19 years or older who were admitted to a general ward at Seoul National University Hospital will be retrospectively reviewed. Hypoxia will be evaluated using two separate reference-standard criteria: oxygen saturation below 94% and administration of oxygen at 4 L/min or more.
Eligible hypoxia-positive and hypoxia-negative datasets will be randomly selected. The selected vital-sign datasets will be analyzed using Vital-PICASO while the device operator is blinded to the reference-standard classification. The software-generated hypoxia risk scores will be compared with the reference-standard classifications to evaluate predictive performance. Because the study uses previously collected medical records, there is no direct participant contact and the software results will not affect patient care.
Looking for future studies?
Notify Me19 year and older
All sexes
Observational
Seoul, South Korea
This study is a retrospective, single-center, superiority-confirmatory clinical performance study conducted at Seoul National University Hospital.
Data Source and Study Population
Electronic medical records will be reviewed for male and female patients aged 19 years or older who were admitted to a general ward for at least 12 hours between January 1, 2023, and May 31, 2025. Clinical data previously used in the development of Vital-PICASO will be excluded.
The collected variables will include systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, body temperature, oxygen saturation, and the corresponding measurement times. Additional variables will include the occurrence, time, and location of hypoxia; oxygen administration status, flow rate, delivery method, and start time; month and year of birth; sex; height and weight when available; do-not-resuscitate status; chronic obstructive pulmonary disease status; pregnancy status; date of admission to the general ward; clinical department; and the vital-sign data collection period.
Reference-Standard Groups
Hypoxia will be evaluated using two separate reference-standard criteria:
For hypoxia-positive datasets, vital-sign data collected for up to 72 hours before the first eligible hypoxia event will be extracted. If hypoxia occurs within 24 hours after admission or transfer to the general ward, all available vital-sign data recorded before the event will be collected. If a patient experiences multiple eligible hypoxia events, only the first eligible event will be included for each reference-standard criterion. A patient who meets both hypoxia criteria may contribute a dataset to both positive-group analyses.
Hypoxia-negative datasets will be selected from patients who did not experience hypoxia during the selected general ward admission. Negative datasets will be randomly selected from the same general wards as the positive datasets and from a time interval comparable with the hypoxia-event reference time or from up to 72 hours after admission to the general ward. Only one eligible data interval will be selected per patient.
Data Selection and Reference-Standard Establishment
To reduce selection bias, candidate positive and negative datasets will be numbered and provided to an independent statistician. The statistician will use R or SAS software to randomly select the required number of datasets and generate a randomly ordered identification-code list.
The initial positive or negative classification will be determined according to the predefined oxygen saturation or oxygen-treatment criterion. To improve the reliability of the study dataset, a clinician with at least 1 year of clinical experience will review the data collection reference time and relevant patient information while blinded to the initial positive or negative classification. The clinician's final determination will be used as the reference standard.
Application of Vital-PICASO
The medical device operator will receive vital-sign datasets identified only by screening numbers and will remain blinded to the reference-standard classification. Each dataset will be analyzed using Vital-PICASO to estimate the risk of hypoxia within 24 hours. The peak risk score and corresponding time within the analysis interval will be recorded.
Performance Evaluation
The software-generated risk scores will be compared with the reference-standard classifications. The two primary performance measures will be:
Each AUROC will be compared with the prespecified comparator performance value of 0.7891. The success criterion for each primary outcome will be met if the lower bound of the 95% confidence interval for the difference between the Vital-PICASO AUROC and the comparator AUROC is greater than zero. The overall study will be considered successful if both primary outcomes meet their respective success criteria.
Secondary performance measures will include area under the precision-recall curve, precision, recall, F1 score, threshold-specific performance, performance by prediction-time interval, cumulative-time performance, sensitivity, specificity, positive predictive value, and negative predictive value.
Planned Analysis Datasets
For the SpO2-below-94% criterion, 2,250 datasets are planned, including 1,125 positive and 1,125 negative datasets. For the oxygen-at-4-L/min-or-more criterion, 546 datasets are planned, including 273 positive and 273 negative datasets. Positive datasets may overlap between the two analyses, and the negative datasets may be used in both analyses.
Because the study uses previously collected electronic medical record data, participants will not undergo any additional examination, treatment, or change in clinical care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
General Criteria
SpO2-Based Hypoxia-Positive Group
SpO2-Based Hypoxia-Negative Group
Oxygen-Treatment-Based Hypoxia-Positive Group
Oxygen-Treatment-Based Hypoxia-Negative Group
Exclusion criteria
Time frame: Within 24 hours before the SpO2-based hypoxia event or during the corresponding reference period for negative cases
The area under the receiver operating characteristic curve (AUROC) is calculated by comparing the hypoxia risk scores generated by Vital-PICASO with the reference-standard classification for the SpO2-based analysis.
Hypoxia-positive cases are defined as cases in which oxygen saturation below 94% occurred in the general ward. Hypoxia-negative cases are selected from patients who did not experience hypoxia during the corresponding general ward admission period.
AUROC ranges from 0 to 1, with a higher value indicating better discrimination between hypoxia-positive and hypoxia-negative cases. The prespecified success criterion is met if the lower bound of the 95% confidence interval for the difference between the Vital-PICASO AUROC and the comparator AUROC of 0.7891 is greater than 0.
Time frame: Within 24 hours before oxygen administration at 4 L/min or more or during the corresponding reference period for negative cases
The area under the receiver operating characteristic curve (AUROC) is calculated by comparing the hypoxia risk scores generated by Vital-PICASO with the reference-standard classification for the oxygen-treatment-based analysis.
Hypoxia-positive cases are defined as cases in which oxygen was administered at a flow rate of 4 L/min or more in the general ward. Hypoxia-negative cases are selected from patients who did not experience hypoxia during the corresponding general ward admission period.
AUROC ranges from 0 to 1, with a higher value indicating better discrimination between hypoxia-positive and hypoxia-negative cases. The prespecified success criterion is met if the lower bound of the 95% confidence interval for the difference between the Vital-PICASO AUROC and the comparator AUROC of 0.7891 is greater than 0.
Time frame: Within 24 hours before the SpO2-based hypoxia event or during the corresponding reference period for negative cases
The area under the precision-recall curve (AUPRC) is calculated using the Vital-PICASO risk scores and the reference-standard classifications for hypoxia defined as oxygen saturation below 94%.
AUPRC summarizes the relationship between precision and recall across possible risk-score thresholds. A higher value indicates better predictive performance.
Time frame: Within 24 hours before oxygen administration at 4 L/min or more or during the corresponding reference period for negative cases
The area under the precision-recall curve (AUPRC) is calculated using the Vital-PICASO risk scores and the reference-standard classifications for hypoxia defined as oxygen administration at a flow rate of 4 L/min or more.
AUPRC summarizes the relationship between precision and recall across possible risk-score thresholds. A higher value indicates better predictive performance.
Time frame: Within the 24-hour prediction window before the hypoxia event or corresponding reference period
Precision, recall, and F1 score are calculated across Vital-PICASO risk-score thresholds. The analyses are performed separately for SpO2-based hypoxia and oxygen-treatment-based hypoxia.
Precision is the proportion of predicted positive cases that are reference-standard positive. Recall is the proportion of reference-standard positive cases that are correctly predicted as positive. The F1 score is the harmonic mean of precision and recall.
Each measure ranges from 0 to 1, with a higher value indicating better classification performance.
Time frame: At prespecified time intervals within 24 hours before the hypoxia event or corresponding reference time point
The predictive performance of Vital-PICASO is evaluated according to the time interval between the software prediction and the hypoxia event or corresponding reference time point.
AUROC, AUPRC, precision, recall, and F1 score may be summarized by prediction-time interval. The analyses are performed separately for SpO2-based hypoxia and oxygen-treatment-based hypoxia.
Time frame: Over cumulative prediction windows of up to 24 hours before the hypoxia event or corresponding reference time point
The predictive performance of Vital-PICASO is evaluated over cumulative prediction windows before the hypoxia event or corresponding reference time point.
AUROC, AUPRC, precision, recall, and F1 score may be summarized for each cumulative prediction window. The analyses are performed separately for SpO2-based hypoxia and oxygen-treatment-based hypoxia.
Time frame: Within the 24-hour prediction window before the hypoxia event or corresponding reference period
Classification performance based on the Vital-PICASO risk scores is evaluated using sensitivity, specificity, positive predictive value, and negative predictive value.
Sensitivity is the proportion of reference-standard positive cases correctly classified as positive. Specificity is the proportion of reference-standard negative cases correctly classified as negative. Positive predictive value is the proportion of predicted positive cases that are reference-standard positive. Negative predictive value is the proportion of predicted negative cases that are reference-standard negative.
The analyses are performed separately for SpO2-based hypoxia and oxygen-treatment-based hypoxia.
Huinno AIM
Industry
Clinical Validity of an AI-Based Biological Signal Analysis Software Vital-PICASO for Predicting the Risk of Hypoxia Within 24 Hrs Using Vital Sign (SBP, DBP, HR, RR, BT, SpO₂) From General Ward Inpatients; A Retrospective, Single-Center, Single-Arm, Superiority-confirmatory Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07720960
Erythropoiesis, Hypoxia
Elche, Alicante, Spain
View Trial DetailsNCT05767385
Cardiovascular Abnormalities, Cardiovascular Diseases
San Francisco, California, United States
View Trial DetailsNCT01542177
Digestive System Diseases, Digestive System Neoplasms
Toronto, Ontario, Canada
View Trial DetailsNCT05354648
Arterial Occlusive Diseases, Arteriosclerosis
View Trial Details